Literature DB >> 17245472

Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?

Nadia Solowij1, Patricia T Michie.   

Abstract

Currently, there is a lot of interest in cannabis use as a risk factor for the development of schizophrenia. Cognitive dysfunction associated with long-term or heavy cannabis use is similar in many respects to the cognitive endophenotypes that have been proposed as vulnerability markers of schizophrenia. In this overview, we examine the similarities between these in the context of the neurobiology underlying cognitive dysfunction, particularly implicating the endogenous cannabinoid system, which plays a significant role in attention, learning and memory, and in general, inhibitory regulatory mechanisms in the brain. Closer examination of the cognitive deficits associated with specific parameters of cannabis use and interactions with neurodevelopmental stages and neural substrates will better inform our understanding of the nature of the association between cannabis use and psychosis. The theoretical and clinical significance of further research in this field is in enhancing our understanding of underlying pathophysiology and improving the provision of treatments for substance use and mental illness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245472      PMCID: PMC1764544     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  286 in total

1.  Neuropsychological performance in long-term cannabis users.

Authors:  H G Pope; A J Gruber; J I Hudson; M A Huestis; D Yurgelun-Todd
Journal:  Arch Gen Psychiatry       Date:  2001-10

2.  Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations.

Authors:  N Hájos; I Katona; S S Naiem; K MacKie; C Ledent; I Mody; T F Freund
Journal:  Eur J Neurosci       Date:  2000-09       Impact factor: 3.386

3.  A multivariate electrophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian family study of schizophrenia.

Authors:  Gregory W Price; Patricia T Michie; Julie Johnston; Hamish Innes-Brown; Aaron Kent; Peter Clissa; Assen V Jablensky
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

4.  Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1.

Authors:  S Leroy; N Griffon; M C Bourdel; J P Olié; M F Poirier; M O Krebs
Journal:  Am J Med Genet       Date:  2001-12-08

5.  Stimulus sequence affects schizophrenia-normal differences in event processing during an auditory oddball task.

Authors:  Casey S Gilmore; Brett A Clementz; Peter F Buckley
Journal:  Brain Res Cogn Brain Res       Date:  2005-07

6.  Prenatal substance exposure: effects on attention and impulsivity of 6-year-olds.

Authors:  S L Leech; G A Richardson; L Goldschmidt; N L Day
Journal:  Neurotoxicol Teratol       Date:  1999 Mar-Apr       Impact factor: 3.763

7.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

8.  Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.

Authors:  A J Hampson; L M Bornheim; M Scanziani; C S Yost; A T Gray; B M Hansen; D J Leonoudakis; P E Bickler
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

9.  Humans with hippocampus damage display severe spatial memory impairments in a virtual Morris water task.

Authors:  Robert S Astur; Laughlin B Taylor; Adam N Mamelak; Linda Philpott; Robert J Sutherland
Journal:  Behav Brain Res       Date:  2002-04-15       Impact factor: 3.332

10.  CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice.

Authors:  Astrid Cannich; Carsten T Wotjak; Kornelia Kamprath; Heike Hermann; Beat Lutz; Giovanni Marsicano
Journal:  Learn Mem       Date:  2004 Sep-Oct       Impact factor: 2.460

View more
  64 in total

1.  Delayed preattentional functioning in early psychosis patients with cannabis use.

Authors:  Nicole Pesa; Daniel F Hermens; Robert A Battisti; Manreena Kaur; Ian B Hickie; Nadia Solowij
Journal:  Psychopharmacology (Berl)       Date:  2012-03-09       Impact factor: 4.530

Review 2.  State of the art treatments for cannabis dependence.

Authors:  Itai Danovitch; David A Gorelick
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

3.  BDNF overexpression prevents cognitive deficit elicited by adolescent cannabis exposure and host susceptibility interaction.

Authors:  Hadar Segal-Gavish; Neta Gazit; Yael Barhum; Tali Ben-Zur; Michal Taler; Shay Henry Hornfeld; Irit Gil-Ad; Abraham Weizman; Inna Slutsky; Minae Niwa; Atsushi Kamiya; Akira Sawa; Daniel Offen; Ran Barzilay
Journal:  Hum Mol Genet       Date:  2017-07-01       Impact factor: 6.150

4.  Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice.

Authors:  Joost Wiskerke; Nicky Stoop; Dustin Schetters; Anton N M Schoffelmeer; Tommy Pattij
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

Review 5.  The endocannabinoid system as a target for modelling psychosis.

Authors:  Dagmar Koethe; Carolin Hoyer; F Markus Leweke
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

6.  Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits.

Authors:  Kirsty Elizabeth Scholes; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

7.  AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.

Authors:  Ruud van Winkel; Nico J M van Beveren; Claudia Simons
Journal:  Neuropsychopharmacology       Date:  2011-07-20       Impact factor: 7.853

Review 8.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

9.  Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia.

Authors:  Johannes Rentzsch; Ada Stadtmann; Christiane Montag; Hagen Kunte; Doris Plöckl; Rainer Hellweg; Jürgen Gallinat; Golo Kronenberg; Maria Christiane Jockers-Scherübl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-17       Impact factor: 5.270

10.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.